{'fraction_non_alphanumeric': 0.034274193548387094, 'fraction_numerical': 0.04233870967741935, 'mean_word_length': 6.417910447761194, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Thyroid and hepatic function after high‐dose 131I‐metaiodobenzylguanidine (131I‐MIBG) therapy for neuroblastoma

131I‐Metaiodobenzylguanidine (131I‐MIBG) provides targeted radiotherapy for children with neuroblastoma, a malignancy of the sympathetic nervous system. Dissociated radioactive iodide may concentrate in the thyroid, and 131I‐MIBG is concentrated in the liver after 131I‐MIBG therapy. The aim of our study was to analyze the effects of 131I‐MIBG therapy on thyroid and liver function.